Fig. 4: Overall survival and cumulative incidence of relapse by GVHD prophylaxis in patients with pre-transplant MRD− vs. MRD+ status. | Bone Marrow Transplantation

Fig. 4: Overall survival and cumulative incidence of relapse by GVHD prophylaxis in patients with pre-transplant MRD− vs. MRD+ status.

From: Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease

Fig. 4

a OS of tacrolimus/sirolimus-based vs. PTCy-based GVHD prophylaxis in MRD− patients. b OS of tacrolimus/sirolimus-based vs. PTCy-based GVHD prophylaxis in MRD+ patients. c CIR of tacrolimus/sirolimus-based vs. PTCy-based GVHD prophylaxis in MRD− patients. d CIR of tacrolimus/sirolimus-based vs. PTCy-based GVHD prophylaxis in MRD+ patients.

Back to article page